openPR Logo
Press release

Burkitt Lymphoma Treatment Market Trends Estimates High Demand By 2026 With Top Players Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc

04-26-2019 03:34 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Burkitt Lymphoma Treatment

Burkitt Lymphoma Treatment

Burkitt lymphoma is a cancer of the lymphatic system, which develops from abnormal B lymphocytes and is characterized by rapid growth. Burkitt lymphoma usually causes lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged 4-7 years, sporadic that occurs globally, and immunodeficiency-associated type that affects people suffering from HIV/AIDS. According to the survey by Cancer Therapy Advisor, Burkitt lymphoma accounts for 30% of pediatric lymphomas and less than 1% of lymphoma cases in adults, especially with a weakened immune system globally. Several cellular therapies are being developed, such as T cell therapy and CAR T cell therapy that use the patient’s own T cells to attack non-Hodgkin's lymphoma cells.

Download The Highly Informative PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1547

Market Dynamics

Rising incidence HIV is expected to augment growth of the Burkitt lymphoma treatment market, as Burkitt lymphoma is an AIDS-defining cancer that is expected to occur more frequently in people suffering from HIV than in the general population. According to the Burkitt Lymphoma Society, the condition accounts for an around 40% of all childhood non Hodgkin lymphoma patients worldwide. It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients. Also, according to the Cancer Therapy Advisor, Burkitt lymphoma (BL) is the most common pediatric cancer with the disease incidence being 2-3 times higher in sub-Saharan Africa, with an estimated incidence of 3–6 cases per 100,000 children per year. The disease is termed as endemic Burkitt lymphoma, where a majority of cases are related to Epstein-Barr virus (EBV).

Moreover, various government and non-government organizations are undertaking research initiatives to launch efficient treatments and create awareness about the rare disease. For instance, the National Cancer Institute initiated the Burkitt Lymphoma Genome Sequencing Project (BLGSP) to explore potential genetic changes in patients suffering from Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. Moreover, researchers at Forgarty International Center and National Cancer Institute are working together to address global health needs related to various cancer types, including Burkitt lymphoma.

Non-profit organization such as Burkitt Lymphoma Society supports and connects patients and caregivers by connecting the patients who have received efficient care for Burkitt lymphoma, thus providing information and creating awareness about the rare medical condition. Also, in 2017, the Lymphoma Research Foundation granted US$ 700,000 to funding innovative research that serves education programs, outreach initiatives, and patient services, thus accelerating the burkitt lymphoma treatment market growth.

Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1547

Competitive Analysis

Key players in this market are offering products to cater to the rising unmet needs of patients suffering from relapsed or refractory Burkitt lymphoma. For instance, Servier, in collaboration with Pfizer Inc., initiated Phase 1 study in 2015 for gene-edited allogeneic CAR19 T-cells (UCART19) to treat relapsed/ refractory acute lymphoblastic leukemia (ALL) in pediatric patients.

Key players operating in the global Burkitt lymphoma treatment market include Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc., Karyopharm Therapeutics, Inc., Boehringer Ingelheim GmbH, and AbbVie Inc.

Regional Dynamics

Regional segmentation of the global Burkitt lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global Burkitt lymphoma treatment market over the forecast period, owing to rising prevalence of lymphoma over the forecast period. According to the survey conducted by WebMD, LLC, 2015, around 1,200 people are diagnosed each year, of which 59% patients are aged 40 years and above in the U.S. Moreover, Burkitt lymphoma shows higher prevalence among HIV infected patients.

The Burkitt lymphoma treatment market in Europe is expected to witness high growth, owing to increasing prevalence of sporadic form of Burkitt lymphoma in the U.K. According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Burkitt Lymphoma Treatment Market Trends Estimates High Demand By 2026 With Top Players Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc here

News-ID: 1720205 • Views: 830

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Burkitt

Burkitt Lymphoma Treatment Market Poised to Expand at a Robust Pace Over 2027
Burkitt Lymphoma Treatment Market research report is the new statistical data source added by CMI. According to this report, Burkitt Lymphoma Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are
Burkitt Lymphoma Treatment Market Revenue Opportunies By Key Vendors Burkitt lym …
Burkitt lymphoma is a cancer of the lymphatic system, which develops from abnormal B lymphocytes and is characterized by rapid growth. Burkitt lymphoma usually causes lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged
Global Burkitt Lymphoma Therapeutics Market 2018 Share, Size, Trends, Applicatio …
Burkitt Lymphoma is one of the rare types of B-cell non-Hodgkin’s lymphoma. It constitutes about 1-2% of all types of non-Hodgkins lymphoma types. It progresses at a very high rate and could be fatal if left untreated during the early stages. Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022. Get Sample@ https://www.researchbeam.com/global-burkitt-lymphoma-therapeutics-2018-2022-market/request-sample Covered in this report The report covers the present scenario and the growth
A Comprehensive Study exploring Burkitt Lymphoma Treatment Market | Key players …
A new business intelligence report released by HTF MI with title “2018-2025 Burkitt Lymphoma Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” that targets and provides comprehensive market analysis with future prospects to 2025. The analysts of the study have garnered extensive research methodologies and data sources (i.e Secondary & Primary Sources) in order to generate collective and useful information that delivers
Burkitt Lymphoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Result …
Burkitt lymphoma is a rare, highly aggressive B-cell non-hodgkin lymphoma. Burkitt lymphoma disease may affect jaw, central nervous system, bowel, kidneys, ovaries, or other organs. Read market summary report : http://bit.ly/2FKQHOg There are three main types of Burkitt lymphoma: endemic, sporadic, and immunodeficiency-related. Endemic Burkitt lymphoma is the most common of the three types, originating in Africa, where it is still the most common childhood cancer. Endemic Burkitt lymphoma is rare
Global Burkitt Lymphoma Treatment Market Healthcare Status, Sales, Trends and In …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Burkitt Lymphoma Treatment Sales Market Research Report (2018-2025)” which provides an outlook of current market value as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% by the end of 2025. The report also studies the Burkitt Lymphoma Treatment Sales market worldwide, especially in North America, China,